L
Lecanemab
Subsidy Information and Financing Scheme
No
Availability of ACE Drug Guidance
Yes
Post-marketing information
Physician Educational Material
Patient Alert Card
Biologics Drug Information Overview
Yes
Active ingredient: Lecanemab
General information
Subsidy Information and Financing Scheme
Not Applicable
Drug Guidance for Subsidy
[NR] Donanemab and lecanemab are not recommended for inclusion on the MOH List of Subsidised Drugs for treating mild cognitive impairment and mild dementia due to Alzheimer’s disease.
[NR] This is because the current available evidence shows that the treatment effects for donanemab and for lecanemab were small with uncertain clinical meaningfulness, and the short trial durations limited the understanding of the treatments’ impact over the full course of the disease.
[NR] Given the uncertainty in clinical benefit and significant additional healthcare resources required to assess treatment eligibility and risks, as well as for regular magnetic resonance imaging (MRI) monitoring, funding these drugs would not represent a cost-effective use of healthcare resources and could place undue strain on the healthcare system.
Post Marketing Information
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Availability information
Formulation | Public Healthcare Institution |
|---|---|
Leqembi Infusion, Solution Concentrate 100 mg/mL |
|